PRP0004 based DAC / Prelude Therap, AbCellera - LARVOL DELTA

Discovery of First-in-Class Precision Antibody Drug Conjugates with a Potent SMARCA 2/4 Dual Degrader Payloads that Safely Achieve Maximal and Tumor Specific Degradation and Efficacy in Mouse Models (GlobeNewswire) - "PRP0004 downregulated multiple drivers of prostate cancer cell growth and survival and resulted in cell death, rationalizing the use of PSMA-targeting antibodies for initial proof-of-concept studies in preclinical models....As expected, dosing with PRP0004 on its own was highly efficacious in prostate cancer xenografts but displayed a narrow therapeutic window. However, when delivered as a payload on anti-PSMA antibodies, the anti-PSMA SMARCA2/4 DACs demonstrate robust SMARCA2 and SMARCA4 degradation and antigen-dependent efficacy in xenograft models while being well-tolerated."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium (GlobeNewswire) - "Prelude Therapeutics Incorporated...announced the publication of three abstracts regarding its SMARCA Degrader Programs at the 36th EORTC-NCI-AACR Symposium....In addition to the updates we will be providing from our Phase 1 trial of PRT3789, we are looking forward to presenting the first preclinical data from our precision degrader antibody conjugates program. These data demonstrate that a highly potent dual SMARCA2/4 degrader payload can be conjugated to an antibody to specifically target tumor cells and safely induce tumor regressions in preclinical models....PRT3789 is a first-in-class, potent and highly selective SMARCA2 degrader, in Phase 1 clinical development in biomarker selected SMARCA4 mutant patients. Enrollment remains on track, and the Company expects to conclude monotherapy dose escalation by year end 2024 and identify the biologically active dose to advance for future trials."

P1 data • Preclinical • Trial status • Non Small Cell Lung Cancer